News

MDC supports antimicrobial resistance research

Amy Schofield 07 February 2018

New drug discovery research to tackle the growing health epidemic of antimicrobial resistance will soon be underway, thanks to an agreement brokered by the Medicines Discovery Catapult.

The Medicines Discovery Catapult will act as a mutual broker between Antimicrobial Discovery Solutions (ADS) Ltd and the University of Dundee to create a neutral space for the partners to explore potential new antimicrobial drug discovery. 

The agreement enables the University of Dundee Drug Discovery Unit to provide its unique chemistry for testing in ADS’s unique assays in a ‘double-blind’ manner where only the neutral Catapult is aware of which chemistry is active.

Only after activity is confirmed will any intellectual property negotiations between the University of Dundee and ADS be required. The deal enables important new chemistry to be combined with new biology without the high barrier of contract negotiations based on what may be discovered. Instead, any negotiations will be conducted only in the event of success and where each party has something tangible to be gained.

The collaboration to tackle the global public health threat of antimicrobial resistance will see the Drug Discovery Unit at the University of Dundee supply around 20,000 chemical compounds. The Medicines Discovery Catapult will act as the custodians of the compounds and will test them against patented assays developed by ADS Ltd, using the Medicines Discovery Catapult facilities at the University of Warwick.

The screen will identify promising compounds on a target of interest, which may have the potential to become effective drugs. Once potential leads have been identified, intellectual property negotiations will take place with a deal brokered with support from the Medicines Discovery Catapult. 

Chris Molloy, Chief Executive of the Medicines Discovery Catapult, said: “This agreement moves the intellectual property discussion to the right place and brings new collaborators together. We’re creating a new space that frees innovation, enables R&D to be done and incentivises all parties to make a fair deal if there is real value demonstrated. All of this helps to bring new medicines to patients faster."

Professor Christopher Dowson, Director of Antimicrobial Discovery Solutions and Professor of Microbiology at the University of Warwick, said: “This arrangement allows us to explore new assays and concentrate on the legalities afterwards. Rather than ignoring intellectual property, we’re pushing it into its rightful place and stopping it from being the stumbling block to meaningful collaboration.”

Professor Ian Gilbert, Head of Chemistry at the Drug Discovery Unit in Dundee, added: “Tackling antimicrobial resistance is one of the most urgent challenges facing humanity, and no single organisation can solve it alone. We hope that working in collaboration with ADS Ltd and Medicines Discovery Catapult will establish good quality hits – turning potentials into drug-like compounds, and moving closer to new types of antibacterials.”

 

 

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.